Status:
COMPLETED
Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept
Lead Sponsor:
Associated Retinal Consultants, Michigan
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Age-Related Macular Degeneration
Eligibility:
All Genders
40+ years
Brief Summary
A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood dr...
Detailed Description
A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood dr...
Eligibility Criteria
Inclusion
- Subjects will be eligible if the following criteria are met:
- Demonstrate worsening of exudation when switched from ranibizumab to aflibercept
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
Exclusion
- Any other condition that the investigator believes would pose a significant hazard to the subject
Key Trial Info
Start Date :
December 22 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT02291887
Start Date
December 22 2014
End Date
July 1 2015
Last Update
November 17 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Associated Retinal Consultants
Royal Oak, Michigan, United States, 48073